And though research is ongoing for anti-PD-1 therapies for cancer, it still might be some time before it reaches clinical trials for helping against sepsis. Opal believes many biotechnology and pharmaceutical companies have been burned by "spectacular failures" in sepsis research.

"We have to convince companies it’s still a viable market," he said. "I don’t wish to suggest there are not obstacles -- there certainly are. But I think the advantage of this strategy, is it's a new way of looking at treatment."




Back to HCB News

More Industry Headlines